Bioengineering of the model lantibiotic nisin

Bioengineered

Volumn 6, Issue 4, 2015, Pages 187-192

  Field, Des ^a   Cotter, Paul D ^b,c   Ross, R Paul ^b,c   Hill, Colin ^a,c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b TEAGASC FOOD RESEARCH CENTRE   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Antimicrobial peptide; Bacteriocin; Lantibiotic; Mutagenesis; Nisin; Post translational modification

Indexed keywords

LANTIBIOTIC; NISIN; ANTIINFECTIVE AGENT; BACTERIOCIN; FOOD PRESERVATIVE;

ANTIBIOTIC BIOSYNTHESIS; ANTIMICROBIAL ACTIVITY; BIOENGINEERING; BIOINFORMATICS; HIGH THROUGHPUT SCREENING; MODULATION; MUTAGENESIS; PHYSICAL CHEMISTRY; PROTEIN PROCESSING; REVIEW; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GRAM POSITIVE BACTERIUM; GROWTH, DEVELOPMENT AND AGING; HUMAN; LACTOCOCCUS LACTIS; METABOLISM; MOLECULAR GENETICS; PROCEDURES; PROTEIN ENGINEERING;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIOCINS; FOOD PRESERVATIVES; GENE EXPRESSION; GRAM-POSITIVE BACTERIA; HUMANS; LACTOCOCCUS LACTIS; MOLECULAR SEQUENCE DATA; NISIN; PROTEIN ENGINEERING; PROTEIN PROCESSING, POST-TRANSLATIONAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84948162012     PISSN: 21655979     EISSN: 21655987     Source Type: Journal    
DOI: 10.1080/21655979.2015.1049781     Document Type: Review

References (55)

1. Sahl H, Bierbaum G. Multiple activities of natural agents such as defensins and bacteriocins suggest a change in strategy when developing new antimicrobials. Microbe 2008; 3: 467-73; PMID: 182646581; http://dx. doi. org/10. 1007/s00248-008-9365-z.
2. Breukink E, de Kruijff B. Lipid II as a target for antibiotics. Nat Rev Drug Discov 2006; 5: 321-32; PMID: 16531990; http://dx. doi. org/10. 1038/nrd2004.
3. Bierbaum G, Szekat C, Josten M, Heidrich C, Kempter C, Jung G, Sahl HG. Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5. Appl Environ Microbiol 1996; 62: 385-92; PMID: 8593044.
4. Rink R, Arkema-Meter A, Baudoin I, Post E, Kuipers A, Nelemans SA, Akanbi MHJ, Moll GN. To protect peptide pharmaceuticals against peptidases. J Pharmacol Toxicol Methods 2010; 61: 210-8; PMID: 20176117; http://dx. doi. org/10. 1016/j. vascn. 2010. 02. 010.
5. Sahl H, Jack R, Bierbaum G. Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. Eur J Biochem 1995; 230: 827-53; PMID: 7601145; http://dx. doi. org/10. 1111/j. 1432-1033. 1995. tb20627. x.
6. Dischinger J, Basi Chipalu S, Bierbaum G. Lantibiotics: promising candidates for future applications in health care. Int J Med Microbiol 2014; 304: 51-62; PMID: 24210177; http://dx. doi. org/10. 1016/j. ijmm. 2013. 09. 003.
7. Rogers LA, Whittier EO. Limiting Factors in the Lactic Fermentation. J Bacteriol 1928; 16: 211-29; PMID: 16559334.
8. Delves-Broughton J. Nisin and its uses as a food preservative. Food Technology 1990; 44: 100-17; PMID: 8775979.
9. Guinane CM, Cotter PD, Hill C, Ross RP. Microbial solutions to microbial problems; lactococcal bacteriocins for the control of undesirable biota in food. J Appl Microbiol 2005; 98: 1316-25; PMID: 15916645; http://dx. doi. org/10. 1111/j. 1365-2672. 2005. 02552. x.
10. Delves-Broughton J. Nisin as a food preservative. Food Australia 2005; 57: 525-7.
11. Sobrino-Lopez A, Martin-Belloso O. Use of nisin and other bacteriocins for preservation of dairy products. Int Dairy J 2008; 18: 329-43; http://dx. doi. org/10. 1016/j. idairyj. 2007. 11. 009.
12. Siegers K, Entian KD. Genes involved in immunity to the lantibiotic nisin produced by Lactococcus lactis 6F3. Appl Environ Microbiol 1995; 61: 1082-9; PMID: 7793910.
13. Engelke G, Gutowski-Eckel Z, Kiesau P, Siegers K, Hammelmann M, Entian KD. Regulation of nisin biosynthesis and immunity in Lactococcus lactis 6F3. Appl Environ Microbiol 1994; 60: 814-25; PMID: 8161176.
14. Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl H, de Kruijff B. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 1999; 286: 2361-4; PMID: 10600751; http://dx. doi. org/10. 1126/science. 286. 5448. 2361.
15. Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, Sahl HG. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 2001; 276: 1772-9; PMID: 11038353; http://dx. doi. org/10. 1074/jbc. M006770200.
16. Bonelli RR, Schneider T, Sahl HG, Wiedemann I. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies. Antimicrob Agents Chemother 2006; 50: 1449-57; PMID: 16569864; http://dx. doi. org/10. 1128/AAC. 50. 4. 1449-1457. 2006.
17. Hsu ST, Breukink E, Tischenko E, Lutters MA, de Kruijff B, Kaptein R, Bonvin AM, van Nuland NA. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat Struct Mol Biol 2004; 11: 963-7; PMID: 15361862; http://dx. doi. org/10. 1038/nsmb830.
18. Piper C, Draper LA, Cotter PD, Ross RP, Hill C. A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2009; 63: 546-51; PMID: 19561147; http://dx. doi. org/10. 1093/jac/dkp221.
19. Kindrachuk J, Jenssen H, Elliott M, Nijnik A, Magrangeas-Janot L, Pasupuleti M, Thorson L, Ma S, Easton DM, Bains M, et al. Manipulation of innate immunity by a bacterial secreted peptide: lantibiotic nisin Z is selectively immunomodulatory. Innate immunity 2013; 19: 315-27; PMID: 23109507; http://dx. doi. org/10. 1177/1753425912461456.
20. Joo NE, Ritchie K, Kamarajan P, Miao D, Kapila YL. Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1. Cancer Med 2012; 1: 295-305; PMID: 23342279; http://dx. doi. org/10. 1002/cam4. 35.
21. Goldstein BP, Wei J, Greenberg K, Novick R. Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model. J Antimicrob Chemother 1998; 42: 277-8; PMID: 9738856; http://dx. doi. org/10. 1093/jac/42. 2. 277.
22. Brumfitt W, Salton MR, Hamilton-Miller JM. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J Antimicrob Chemother 2002; 50: 731-4; PMID: 12407132; http://dx. doi. org/10. 1093/jac/dkf190.
23. Severina E, Severin A, Tomasz A. Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens. J Antimicrob Chemother 1998; 41: 341-7; PMID: 9578160; http://dx. doi. org/10. 1093/jac/41. 3. 341.
24. Cao LT, Wu JQ, Xie F, Hu SH, Mo Y. Efficacy of nisin in treatment of clinical mastitis in lactating dairy cows. J Dairy Sci 2007; 90: 3980-5; PMID: 17639009; http://dx. doi. org/10. 3168/jds. 2007-0153.
25. Fernandez L, Delgado S, Herrero H, Maldonado A, Rodriguez JM. The bacteriocin nisin, an effective agent for the treatment of staphylococcal mastitis during lactation. J Hum Lact 2008; 24: 311-6; PMID: 18689718; http://dx. doi. org/10. 1177/0890334408317435.
26. Cortés J, Appleyard AN, Dawson MJ, David AH. Chapter 22 Whole cell generation of lantibiotic variants. Methods in Enzymology: Academic Press, 2009: 559-74.
27. Kaletta C, Entian KD. Nisin, a peptide antibiotic: cloning and sequencing of the nisA gene and posttranslational processing of its peptide product. J Bacteriol 1989; 171: 1597-601; PMID: 2493449.
28. Mulders JW, Boerrigter IJ, Rollema HS, Siezen RJ, de Vos WM. Identification and characterization of the lantibiotic nisin Z, a natural nisin variant. Eur J Biochem 1991; 201: 581-4; PMID: 1935953; http://dx. doi. org/10. 1111/j. 1432-1033. 1991. tb16317. x.
29. Zendo T, Fukao M, Ueda K, Higuchi T, Nakayama J, Sonomoto K. Identification of the lantibiotic nisin Q, a new natural nisin variant produced by Lactococcus lactis 61-14 isolated from a river in Japan. Biosci Biotechnol Biochem 2003; 67: 1616-9; PMID: 12913315; http://dx. doi. org/10. 1271/bbb. 67. 1616.
30. de Kwaadsteniet M, Ten Doeschate K, Dicks LM. Characterization of the structural gene encoding nisin F, a new lantibiotic produced by Lactococcus lactis subsp. lactis isolated from fresh water catfish (Clarias gariepinus). Appl Environ Microbiol 2008; 74: 547-9; PMID: 18039827; http://dx. doi. org/10. 1128/AEM. 01862-07.
31. Wirawan RE, Klesse NA, Jack RW, Tagg JR. Molecular and genetic characterization of a novel nisin variant produced by Streptococcus uberis. Appl Environ Microbiol 2006; 72: 1148-56; PMID: 16461661; http://dx. doi. org/10. 1128/AEM. 72. 2. 1148-1156. 2006.
32. Piper C, Hill C, Cotter PD, Ross RP. Bioengineering of a Nisin A-producing Lactococcus lactis to create isogenic strains producing the natural variants Nisin F, Q and Z. Microb Biotechnol 2011; 4: 375-82; PMID: 21375711; http://dx. doi. org/10. 1111/j. 1751-7915. 2010. 00207. x.
33. Perin LM, Nero LA. Antagonistic lactic acid bacteria isolated from goat milk and identification of a novel nisin variant Lactococcus lactis. BMC Microbiol 2014; 14: 36; PMID: 24521354; http://dx. doi. org/10. 1186/1471-2180-14-36.
34. Zhang Q, Yu Y, Velasquez JE, van der Donk WA. Evolution of lanthipeptide synthetases. Proc Natl Acad Sci U S A 2012; 109: 18361-6; PMID: 23071302; http://dx. doi. org/10. 1073/pnas. 1210393109.
35. Garg N, Tang W, Goto Y, Nair SK, van der Donk WA. Lantibiotics from Geobacillus thermodenitrificans. Proc Natl Acad Sci U S A 2012; 109: 5241-6; PMID: 22431611; http://dx. doi. org/10. 1073/pnas. 1116815109.
36. Kuipers OP, Rollema HS, Yap WM, Boot HJ, Siezen RJ, de Vos WM. Engineering dehydrated amino acid residues in the antimicrobial peptide nisin. J Biol Chem 1992; 267: 24340-6; PMID: 1447185.
37. Rollema HS, Kuipers OP, Both P, de Vos WM, Siezen RJ. Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl Environ Microbiol 1995; 61: 2873-8; PMID: 7487019.
38. Demel RA, Peelen T, Siezen RJ, De Kruijff B, Kuipers OP. Nisin Z, mutant nisin Z and lacticin 481 interactions with anionic lipids correlate with antimicrobial activity. A monolayer study. Eur J Biochem 1996; 235: 267-74; PMID: 8631341; http://dx. doi. org/10. 1111/j. 1432-1033. 1996. 00267. x.
39. Van Kraaij C, Breukink E, Rollema HS, Siezen RJ, Demel RA, De Kruijff B, Kuipers OP. Influence of charge differences in the C-terminal part of nisin on antimicrobial activity and signaling capacity. Eur J Biochem 1997; 247: 114-20; PMID: 9249016; http://dx. doi. org/10. 1111/j. 1432-1033. 1997. 00114. x.
40. Kuipers OP, Bierbaum G, Ottenwalder B, Dodd HM, Horn N, Metzger J, Kupke T, Gnau V, Bongers R, van den Bogaard P, et al. Protein engineering of lantibiotics. Antonie Van Leeuwenhoek 1996; 69: 161-69; PMID: 8775976; http://dx. doi. org/10. 1007/BF00399421.
41. Cotter PD, Hill C, Ross RP. Bacterial lantibiotics: strategies to improve therapeutic potential. Curr Protein Pept Sci 2005; 6: 61-75; PMID: 15638769; http://dx. doi. org/10. 2174/1389203053027584.
42. Lubelski J, Rink R, Khusainov R, Moll GN, Kuipers OP. Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. Cell Mol Life Sci 2007; 65: 455-76; PMID: 17965835; http://dx. doi. org/10. 1007/s00018-007-7171-2.
43. Yuan J, Zhang ZZ, Chen XZ, Yang W, Huan LD. Sitedirected mutagenesis of the hinge region of nisinZ and properties of nisinZ mutants. Appl Microbiol Biotechnol 2004; 64: 806-15; PMID: 15048591; http://dx. doi. org/10. 1007/s00253-004-1599-1.
44. Field D, O'Connor PM, Cotter PD, Hill C, Ross RP. The generation of nisin variants with enhanced activity against specific gram-positive pathogens. Mol Microbiol 2008; 69: 218-30; PMID: 18485077; http://dx. doi. org/10. 1111/j. 1365-2958. 2008. 06279. x.
45. Carroll J, Field D, O' Connor PM, Cotter PD, Coffey A, Hill C, Ross RP, O' Mahony J. The gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs. Bioengineered Bugs 2010; 1: 408-12; PMID: 21468208; http://dx. doi. org/10. 4161/bbug. 1. 6. 13642.
46. Field D, Quigley L, O'Connor PM, Rea MC, Daly K, Cotter PD, Hill C, Ross RP. Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V. Microb Biotechnol 2010; 3: 473-86; PMID: 21255345; http://dx. doi. org/10. 1111/j. 1751-7915. 2010. 00184. x.
47. Campion A, Casey PG, Field D, Cotter PD, Hill C, Ross RP. In vivo activity of nisin A and nisin V against Listeria monocytogenes in mice. BMC Microbiol 2013; 13: 23; PMID: 23374279; http://dx. doi. org/10. 1186/1471-2180-13-23.
48. Healy B, Field D, O'Connor PM, Hill C, Cotter PD, Ross RP. Intensive mutagenesis of the nisin hinge leads to the rational design of enhanced derivatives. PLoS One 2013; 8: e79563; PMID: 24244524; http://dx. doi. org/10. 1371/journal. pone. 0079563.
49. Zhou L, van Heel AL, Kuipers OP. The length of a lantibiotic hinge region has profound influence on antimicrobial activity and host specificity. Frontiers in microbiology 2015; 6; PMID: AMBIGUOUS; http://dx. doi. org/10. 3389/fmicb. 2015. 00011.
50. Field D, Begley M, O'Connor PM, Daly KM, Hugenholtz F, Cotter PD, Hill C, Ross RP. Bioengineered Nisin A Derivatives with Enhanced Activity against Both Gram Positive and Gram Negative Pathogens. PLoS ONE 2012; 7: e46884; PMID: 23056510; http://dx. doi. org/10. 1371/journal. pone. 0046884.
51. Molloy EM, Field D, PM OC, Cotter PD, Hill C, Ross RP. Saturation mutagenesis of lysine 12 leads to the identification of derivatives of nisin A with enhanced antimicrobial activity. PLoS One 2013; 8: e58530; PMID: 23505531; http://dx. doi. org/10. 1371/journal. pone. 0058530.
52. de Vos WM, Mulders JW, Siezen RJ, Hugenholtz J, Kuipers OP. Properties of nisin Z and distribution of its gene, nisZ, in Lactococcus lactis. Appl Environ Microbiol 1993; 59: 213-8; PMID: 8439149.
53. Rouse S, Field D, Daly KM, O'Connor PM, Cotter PD, Hill C, Ross RP. Bioengineered nisin derivatives with enhanced activity in complex matrices. Microb Biotechnol 2012; 5: 501-8; PMID: 22260415; http://dx. doi. org/10. 1111/j. 1751-7915. 2011. 00324. x.
54. Kong W, Lu T. Cloning and optimization of a nisin biosynthesis pathway for bacteriocin harvest. ACS synthetic biology 2014; 3: 439-45; PMID: 24847677; http://dx. doi. org/10. 1021/sb500225r.
55. Slootweg JC, Liskamp RM, Rijkers DT. Scalable purification of the lantibiotic nisin and isolation of chemical/enzymatic cleavage fragments suitable for semi-synthesis. Journal of peptide science: an official publication of the European Peptide Society 2013; 19: 692-9; PMID: 24023046; http://dx. doi. org/10. 1002/psc. 2551.